100 related articles for article (PubMed ID: 10685657)
21. Histamine and interleukin-2 in acute myelogenous leukemia.
Hellstrand K; Mellqvist UH; Wallhult E; Carneskog J; Kimby E; Celsing F; Brune M
Leuk Lymphoma; 1997 Nov; 27(5-6):429-38. PubMed ID: 9477124
[TBL] [Abstract][Full Text] [Related]
22. Post-remission therapy of adult acute myeloid leukemia: high dose cytosine-arabinoside versus other consolidation regimens.
Zeremski V; Savić A
Med Pregl; 2014; 67(3-4):83-90. PubMed ID: 24961049
[TBL] [Abstract][Full Text] [Related]
23. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy.
Massumoto C; Benyunes MC; Sale G; Beauchamp M; York A; Thompson JA; Buckner CD; Fefer A
Bone Marrow Transplant; 1996 Mar; 17(3):351-6. PubMed ID: 8704686
[TBL] [Abstract][Full Text] [Related]
24. Survival outcome following isolated central nervous system relapse treated with additional chemotherapy and craniospinal irradiation in childhood acute lymphoblastic leukemia.
Kumar P; Kun LE; Hustu HO; Mulhern RK; Hancock ML; Coffey D; Rivera GK
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):477-83. PubMed ID: 7852109
[TBL] [Abstract][Full Text] [Related]
25. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
[TBL] [Abstract][Full Text] [Related]
26. Achievement and maintenance of complete remission in a patient with acute myelogenous leukemia after weekly administration of interleukin-2.
Speletas M; Ritis K; Bourikas G
Haematologica; 1996; 81(4):346-8. PubMed ID: 8870381
[TBL] [Abstract][Full Text] [Related]
27. Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia.
Lange BJ; Yang RK; Gan J; Hank JA; Sievers EL; Alonzo TA; Gerbing RB; Sondel PM
Pediatr Blood Cancer; 2011 Sep; 57(3):398-405. PubMed ID: 21681921
[TBL] [Abstract][Full Text] [Related]
28. A phase I study of interleukin-2 in children with cancer.
Roper M; Smith MA; Sondel PM; Gillespie A; Reaman GH; Hammond GD; Levitt D; Rosolen A; Colamonici OR; Neckers LM
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):305-11. PubMed ID: 1456395
[TBL] [Abstract][Full Text] [Related]
29. Intravenous 6-mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group study CCG 1922.
Tolar J; Bostrom BC; La MK; Sather HN
Pediatr Blood Cancer; 2005 Jul; 45(1):5-9. PubMed ID: 15481062
[TBL] [Abstract][Full Text] [Related]
30. Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the Children's cancer group study CCG-2891.
Gamis AS; Howells WB; DeSwarte-Wallace J; Feusner JH; Buckley JD; Woods WG
J Clin Oncol; 2000 May; 18(9):1845-55. PubMed ID: 10784625
[TBL] [Abstract][Full Text] [Related]
31. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse.
Maraninchi D; Blaise D; Viens P; Brandely M; Olive D; Lopez M; Sainty D; Marit G; Stoppa AM; Reiffers J
Blood; 1991 Nov; 78(9):2182-7. PubMed ID: 1932739
[TBL] [Abstract][Full Text] [Related]
32. [Acute myelogenous leukemia in children: results of the cooperative BFM-78 therapy study after 3 3/4 years].
Creutzig U; Ritter J; Langermann HJ; Riehm H; Henze G; Niethammer D; Jürgens H; Stollmann B; Lasson U; Kabisch H; Wahlen W; Löffler H; Schellong G
Klin Padiatr; 1983; 195(3):152-60. PubMed ID: 6576202
[TBL] [Abstract][Full Text] [Related]
33. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.
Pautas C; Merabet F; Thomas X; Raffoux E; Gardin C; Corm S; Bourhis JH; Reman O; Turlure P; Contentin N; de Revel T; Rousselot P; Preudhomme C; Bordessoule D; Fenaux P; Terré C; Michallet M; Dombret H; Chevret S; Castaigne S
J Clin Oncol; 2010 Feb; 28(5):808-14. PubMed ID: 20048183
[TBL] [Abstract][Full Text] [Related]
34. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
Haas R; Ho AD; Del Valle F; Fischer JT; Ehrhardt R; Döhner H; Witt B; Huberts H; Kaplan E; Hunstein W
Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968
[TBL] [Abstract][Full Text] [Related]
35. Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: a pilot study.
Macdonald D; Jiang YZ; Gordon AA; Mahendra P; Oskam R; Palmer PA; Franks CR; Barrett AJ
Leuk Res; 1990; 14(11-12):967-73. PubMed ID: 2280612
[TBL] [Abstract][Full Text] [Related]
36. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
Jehn U; Heinemann V; Wilmanns W
Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of carboplatin as a treatment for children with acute leukemia recurring in bone marrow: a report of the Children's Cancer Group.
Ettinger LJ; Ivy P; Gaynon PS; Ettinger AG; Liu-Mares W; Krailo MD
Cancer; 1997 Jul; 80(2):311-6. PubMed ID: 9217045
[TBL] [Abstract][Full Text] [Related]
38. [Prognosis of children with acute myelocytic leukemia after first relapse].
Creutzig U; Ritter J; Boos J; Zimmermann M; Bender-Götze C; Stahnke K
Klin Padiatr; 1998; 210(4):207-11. PubMed ID: 9743954
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia.
Meloni G; Foa R; Vignetti M; Guarini A; Fenu S; Tosti S; Tos AG; Mandelli F
Blood; 1994 Oct; 84(7):2158-63. PubMed ID: 7919330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
